Key result
Switching from warfarin to a direct oral anticoagulant was evaluated for its effects on stroke and major bleeding rates in patients grouped by time-in-therapeutic range thresholds.
Why the study?
Does switching from warfarin to a DOAC improve stroke and major bleeding rates in patients based on pre-switch time-in-therapeutic range?
Does switching from warfarin to a DOAC improve stroke and major bleeding rates in patients based on pre-switch time-in-therapeutic range?
Should not yet change switching practices based on TTR alone; leaves open whether DOAC benefits vary by prior warfarin control.
This cohort study evaluates stroke and major bleeding rates before and after switching from warfarin to a direct oral anticoagulant (DOAC) in patients grouped by pre-switch time-in-therapeutic range guideline thresholds.
No takes yet. Share an insight, caveat, or question.
Haymart et al. (2022) studied this question. Switching from warfarin to a direct oral anticoagulant was evaluated for its effects on stroke and major bleeding rates in patients grouped by time-in-therapeutic range thresholds.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: